As biologics move from fed-batch norms to continuous bioprocessing, traditional approaches to process characterization and validation are no longer enough. To achieve robust, scalable processes that endure through a therapy’s lifecycle and enable commercialization, control strategies must evolve.

In this session, FUJIFILM Biotechnologies experts will share how the MaruX™ platform—single-use bioreactors run in perfusion with a fully connected downstream composed of single-use SymphonX™ units enables a new paradigm. By defining processes in high-cycle, small sub-batches, teams can generate richer data and de-risk validation in continuous operations.

Join us to see how next-generation process design unlocks speed, consistency, and compliance for continuous bioprocessing.